[1] |
中华医学会心血管病学分会肺血管病学组, 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(12): 933 – 964. doi: 10.3760/cma.j.issn.0253-3758.2018.12.006
|
[2] |
Coeytaux RR, Schmit KM, Kraft BD, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Chest, 2014, 145(5): 1055 – 1063. doi: 10.1378/chest.13-1864
|
[3] |
Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives[J]. Eur Respir J, 2019, 53(1): 1801887. doi: 10.1183/13993003.01887-2018
|
[4] |
Olschewski H, Olschewski A, Rose F, et al. Physiologic basis for the treatment of pulmonary hypertension[J]. J Lab Clin Med, 2001, 138(5): 287 – 297. doi: 10.1067/mlc.2001.119329
|
[5] |
Sitbon O, Vonk Noordegraaf A. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience[J]. Eur Respir Rev, 2017, 26(143): 160055. doi: 10.1183/16000617.0055-2016
|
[6] |
Grünig E, Benjamin N, Lange TJ, et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial[J]. Respiration, 2016, 92(6): 362 – 370. doi: 10.1159/000450759
|
[7] |
Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial[J]. Chest, 2012, 142(6): 1383 – 1390. doi: 10.1378/chest.11-2212
|
[8] |
Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension[J]. Respir Med, 2010, 104(5): 731 – 740. doi: 10.1016/j.rmed.2010.01.008
|
[9] |
Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension[J]. Eur Respir J, 2009, 33(6): 1354 – 1360. doi: 10.1183/09031936.00169608
|
[10] |
Galiè N, Humbert M, Vachiéry JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial[J]. J Am Coll Cardiol, 2002, 39(9): 1496 – 1502. doi: 10.1016/S0735-1097(02)01786-2
|
[11] |
Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2003, 41(12): 2119 – 2125. doi: 10.1016/S0735-1097(03)00463-7
|
[12] |
Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension[J]. Eur Respir J, 2012, 40(4): 874 – 880. doi: 10.1183/09031936.00137511
|
[13] |
Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2015, 373(26): 2522 – 2533. doi: 10.1056/NEJMoa1503184
|
[14] |
Picken C, Fragkos KC, Eddama M, et al. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis[J]. J Clin Med, 2019, 8(4): 481. doi: 10.3390/jcm8040481
|
[15] |
Roscigno R, Vaughn T, Anderson S, et al. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil[J]. Pulm Circ, 2020, 10(4): 2045894020971509. doi: 10.1177/2045894020971509
|